The WAP four-disulfide core domain protein HE4: A novel biomarker for heart failure

JACC: Heart Failure

Volumn 1, Issue 2, 2013, Pages 164-169

  De Boer, Rudolf A ^a   Cao, Qi ^a   Postmus, Douwe ^a   Damman, Kevin ^a   Voors, Adriaan A ^a   Jaarsma, Tiny ^a,b   Van Veldhuisen, Dirk J ^a   Arnold, William D ^c   Hillege, Hans L ^a   Silljé, Herman H W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Alere San Diego Inc   (United States)

Author keywords

Biomarker; HE4; Heart failure; Prognostic marker; WFDC 2

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15; HE4 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK ASSESSMENT; RISK FACTOR;

BIOMARKER; HE4; HEART FAILURE; PROGNOSTIC MARKER; WFDC-2;

AGED; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; PROTEINS;

EID: 84877998802     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2012.11.005     Document Type: Article

References (26)

1. Stewart S., MacIntyre K., Hole D.J., Capewell S., McMurray J.J. More "malignant" than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001, 3:315-322.
2. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869. Taskforce.
3. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society For Heart And Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
4. van Kimmenade R.R., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
5. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811-817.
6. Anand I.S., Kempf T., Rector T.S., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 2010, 122:1387-1395.
7. Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012, 9:347-359.
8. Montagnana M., Danese E., Giudici S., et al. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem 2011, 55:1-20.
9. Jaarsma T., Van Der Wal M.H., Hogenhuis J., et al. Design and methodology of the COACH study: a multicenter randomised coordinating study evaluating outcomes of advising and counselling in heart failure. Eur J Heart Fail 2004, 6:227-233.
10. Jaarsma T., van der Wal M.H., Lesman-Leegte I., et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating study evaluating Outcomes of Advising and Counseling in Heart failure (COACH). Arch Intern Med 2008, 168:316-324.
11. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
12. Postmus D., van Veldhuisen D.J., Jaarsma T., et al. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail 2012, 14:168-175.
13. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991, 45:350-357.
14. Bingle L., Singleton V., Bingle C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21:2768-2773.
15. Bingle L., Cross S.S., High A.S., et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006, 7:61.
16. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006, 19:847-853.
17. Hochstrasser K., Reichert R., Schwarz S., Werle E. Isolation and characterisation of a protease inhibitor from human bronchial secretion. Hoppe Seylers Z Physiol Chem 1972, 353:221-226.
18. Hochstrasser K., Albrecht G.J., Schonberger O.L., Rasche B., Lempart K. An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization. Hoppe Seylers Z Physiol Chem 1981, 362:1369-1375.
19. Bingle C.D., Vyakarnam A. Novel innate immune functions of the whey acidic protein family. Trends Immunol 2008, 29:444-453.
20. Scott A., Weldon S., Taggart C.C. SLPI and elafin: multifunctional antiproteases of the WFDC family. Biochem Soc Trans 2011, 39:1437-1440.
21. Kempf T., Zarbock A., Widera C., et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011, 17:581-588.
22. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
23. Hellstrom I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
24. Huhtinen K., Suvitie P., Hiissa J., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009, 100:1315-1319.
25. Montagnana M., Lippi G., Danese E., Franchi M., Guidi G.C. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer 2009, 101:548.
26. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.